Table 1.
Demographic and Clinical Features. Data for progressive (n=792) and non-progressive (n=376) nodules are displayed as mean (standard deviation) for continuous variables and percent (count) for categorical variables. Age is represented in years, and lesion volumes are measured in voxels. P-values were computed for difference in means (two-sample T-test) or proportions (Chi-squared test) between the progression and non-progression groups for continuous and categorical variables, respectively. Statistically significant p-values are highlighted in bold. MaxSUV: maximum standardized uptake value, SD: standard deviation; SCLC: small cell lung carcinoma; NSCLC: non-small cell lung carcinoma.
| Clinical Feature Summary | |||
|---|---|---|---|
| Variable | Progression | No Progression | P-value |
| Total Nodule Count | 792 | 376 | |
| Age (SD) | 66.54 (13.93) | 69.66 (10.69) | <0.001 |
| MaxSUV Uptake (SD) | 8.64 (7.40) | 9.72 (7.34) | 0.020 |
| CT Lesion Volume (SD) | 26,097 (66,850) | 26,012 (72,518) | 0.984 |
| PET Lesion Volume (SD) | 27,575 (68,507) | 27,626 (73,039) | 0.991 |
| Sex (Nodule Count) | 0.953 | ||
| Male | 48.5% (384) | 48.7% (183) | |
| Female | 51.5% (408) | 51.3% (193) | |
| Diagnosis Method (Nodule Count) | 0.235 | ||
| Biopsy | 41.8% (331) | 45.5% (171) | |
| Surgery | 58.2% (461) | 54.5% (205) | |
| Race (Nodule Count) | <0.001 | ||
| White | 68.6% (543) | 75.3% (283) | |
| African American | 15.9% (126) | 12.0% (45) | |
| Asian/Pacific Islander | 12.5% (99) | 12.8% (48) | |
| Other | 1.1% (9) | 0% (0) | |
| Unknown | 1.9% (15) | 0% (0) | |
| Treatments (Nodule Count) | |||
| Chemotherapy | 27.0% (215) | 3.0% (11) | <0.001 |
| Radiation therapy | 26.5% (211) | 16.5% (53) | <0.001 |
| Immunotherapy | 8.1% (64) | 3.3% (12) | 0.002 |
| Histologically Confirmed Diagnosis Summary | |||
|---|---|---|---|
| Progression (Nodule Count) | No Progression (Nodule Count) | ||
| Adenocarcinoma | 62.4% (494) | Adenocarcinoma | 65.4% (246) |
| Squamous Cell Carcinoma | 14.9% (118) | Squamous Cell Carcinoma | 16.2% (61) |
| Lymphoma | 4.2% (33) | Lymphoma | 1.6% (6) |
| Metastasis | 7.2% (57) | Metastasis | 2.7% (10) |
| Unspecified SCLC | 4.7% (37) | Unspecified SCLC | 7.2% (27) |
| Unspecified NSCLC | 2.9% (23) | Unspecified NSCLC | 4.8% (18) |
| Carcinoid | 1.5% (12) | Carcinoid | 1.3% (5) |
| Neuroendocrine | 1.3% (10) | Neuroendocrine | 0% (0) |
| Other | 1.0% (8) | Other | 0.8% (3) |